L-Glutamine: Independent Evidence on Leaky Gut, IBS, IBD & Critical Illness Safety

by
Key takeaways
  • L-glutamine is a conditionally essential amino acid and the primary fuel for intestinal cells (enterocytes); the strongest single piece of human evidence for a gut claim is Zhou et al. 2019 in Gut, an NIH/NIDDK-funded, conflict-free RCT showing 15 g/day normalized intestinal permeability and produced a 79.6% vs. 5.8% response rate — but only in a narrow subgroup: post-infectious diarrhea-predominant IBS with measured hyperpermeability.
  • Outside that specific subgroup, general "leaky gut" repair claims are not supported by human trials and rely on animal/in-vitro data excluded from this review; Crohn’s disease shows no benefit in a Cochrane review, and ulcerative colitis/IBD broadly shows no effect in a 2021 systematic review.
  • The most important safety finding is not about the gut at all: in critically ill adults with multi-organ failure, the large, publicly funded REDOXS trial (NEJM 2013) found high-dose glutamine increased mortality (adjusted OR 1.28), reversing decades of positive industry-shaped parenteral-nutrition literature.
  • A 47-RCT meta-analysis found no routine mortality benefit in critical illness overall, with only a weak subgroup signal in severe burns (Sun et al. 2021); contemporary critical-care guidelines no longer recommend routine high-dose glutamine.
  • The only FDA-approved pharmaceutical use of L-glutamine (Endari) is for reducing pain crises in sickle cell disease — unrelated to gut health; marketing that cites "FDA-recognized" glutamine without this context is misleading.
  • Pure City Research grade: Weak-to-Moderate for gut health overall — genuine benefit in one narrow, well-studied subgroup, no benefit in IBD, and a documented harm signal at high doses in the critically ill.

L-glutamine is the body’s most abundant free amino acid and the main respiratory fuel for the cells lining the gut, which is the mechanistic basis for most "gut healing" marketing claims. In humans, however, the evidence is narrow and mixed: one strong, independent RCT shows real benefit in a specific post-infectious IBS-D subgroup with measured hyperpermeability, but broader "leaky gut" repair, Crohn’s disease, and ulcerative colitis all lack supporting human evidence. In critically ill patients — historically glutamine’s best-marketed use — the largest independent trial found increased mortality at high doses. This article covers what L-glutamine is, the forms sold, the claim-by-claim human evidence, safety and interactions, funding influences, and regulatory status.

Table of contents

Claim Evidence Source Funding/conflict Strength
Intestinal permeability, post-infectious IBS-D with measured hyperpermeability Double-blind RCT: 15 g/day normalized urinary lactulose/mannitol ratio; 79.6% vs. 5.8% clinical responders Zhou et al., Gut 2019 NIH/NIDDK grants; authors declared no competing interests — independent Moderate (narrow subgroup)
"Leaky gut" repair, general/healthy population No adequate human RCT; claims rest on animal/in-vitro data — — Insufficient
Irritable bowel syndrome, general (IBS-C, mixed, non-post-infectious) No adequate independent RCT beyond the post-infectious IBS-D subgroup Zhou et al., Gut 2019 NIH-funded trial covers only the narrow subgroup Weak
Crohn’s disease (induction of remission) Cochrane review: 2 RCTs, 42 patients total, no benefit; GRADE quality low/very low Akobeng et al., Cochrane 2016 (full text) Cochrane; academic authors, no commercial funding disclosed — independent Insufficient/Contested
Ulcerative colitis / IBD broadly Systematic review of 7 RCTs: no effect on disease course, permeability, symptoms, or inflammation markers Severo et al., Clin Nutr ESPEN 2021 Academic (Brazilian public universities) — independent Insufficient
Critical illness, multi-organ failure (general) 1,223-patient RCT: increased 28-day, in-hospital, and 6-month mortality (adjusted OR 1.28) Heyland et al. (REDOXS), NEJM 2013 Canadian Institutes of Health Research (CIHR) — public, independent Contested (harm signal)
Critical illness, GI failure on parenteral nutrition 502-patient RCT: no reduction in new infections (OR 1.07) or mortality benefit Andrews et al. (SIGNET), BMJ 2011 Chief Scientist Office, Scotland — public, independent No benefit
Critical illness, pooled evidence Meta-analysis of 47 RCTs (6,198 patients): no significant hospital-mortality reduction; shortened ventilation duration; weak burns-subgroup signal Sun et al., Ann Palliat Med 2021 Academic meta-analysis Weak (burns subgroup only)
Exercise, immune function, muscle preservation Surrogate/biochemical markers only; no consistent clinical benefit in athletes with adequate protein intake Cruzat et al., Nutrients 2018 Academic review Weak
Sickle cell disease pain crises (not a gut claim) RCT evidence supporting FDA drug approval (Endari) LiverTox, NIH NBK573011 Industry (Emmaus Medical) drug approval pathway Strong (unrelated to gut health)

What L-glutamine is

L-glutamine is the most abundant free amino acid in human plasma and skeletal muscle. It is classified as conditionally essential: the body normally makes enough on its own, but during catabolic stress — trauma, sepsis, burns, major surgery, or critical illness — demand can outstrip the body’s own supply, making dietary or intravenous glutamine potentially important in those specific settings (Kim & Kim, Int J Mol Sci 2017; Cruzat et al., Nutrients 2018).

Glutamine is a primary respiratory fuel for enterocytes (the absorptive cells lining the small intestine) and for rapidly dividing immune cells. This single fact — that gut cells burn glutamine for energy at a high rate — is the mechanistic basis for nearly every gut-health and immune-support claim made about the supplement (Cruzat et al., Nutrients 2018). It does not automatically follow that adding more glutamine to a normal diet improves gut barrier function in people who are not glutamine-depleted, which is the central tension this article works through claim by claim.

All forms and grades

Form Description Where used Why this form
Free L-glutamine powder / capsules The dominant consumer supplement form; plain crystalline amino acid Oral dietary supplements, sports nutrition, the Zhou et al. IBS-D RCT (15 g/day oral) Inexpensive and simple, but relatively unstable in aqueous solution and degrades under heat sterilization, which limits its use in manufactured liquid or heat-processed clinical formulas
L-alanyl-L-glutamine dipeptide (e.g., Dipeptiven) A stabilized dipeptide of glutamine bonded to alanine Used clinically in parenteral (IV) nutrition Free glutamine has poor aqueous solubility (~35 g/L) and heat instability that prevent it from being autoclaved into standard parenteral nutrition bags; the dipeptide form is highly soluble and heat-stable, allowing terminal sterilization and a workable shelf life (Fürst et al., glutamine dipeptides in parenteral nutrition; Vanek et al. review)
Glycyl-L-glutamine dipeptide A related stabilized dipeptide, glutamine bonded to glycine Also used in parenteral nutrition formulations Same solubility/heat-stability rationale as alanyl-glutamine (Vanek et al. review)
Endari (pharmaceutical-grade L-glutamine) FDA-approved prescription drug formulation of L-glutamine Sickle cell disease, to reduce acute painful crises — not a gut-health product Approved based on RCT evidence specific to sickle cell disease (LiverTox NBK573011)

The distinction between free-form powder and the clinical dipeptide forms matters mainly for stability and delivery route, not for a fundamentally different mechanism of action once glutamine is available to cells — but it explains why hospital-grade parenteral nutrition trials used dipeptides while the oral human trials discussed below used plain free-form L-glutamine powder.

How it works

Enterocytes and other rapidly dividing cells (including many immune cells) preferentially oxidize glutamine for energy, more so than glucose in some contexts. The proposed mechanism behind gut-barrier claims is that adequate glutamine supply supports enterocyte energy metabolism, proliferation, and tight-junction integrity, which in principle could reduce intestinal permeability under conditions of gut stress (Cruzat et al., Nutrients 2018; Kim & Kim, Int J Mol Sci 2017). Much of the detailed cell-biology and gut-integrity mechanism data underpinning this story comes from rodent and cell-culture models; that mechanistic work is not used here to support any human efficacy or safety conclusion and is noted only as background for why the claim is biologically plausible.

In critical illness, glutamine is also proposed to support immune cell function and antioxidant capacity (as a precursor to glutathione) during severe catabolic stress — the rationale that drove decades of parenteral-nutrition research before the largest independent trials reversed the field’s conclusions (see the critical illness section below).

Intestinal permeability and "leaky gut"

This is where L-glutamine has its single strongest piece of independent human evidence — and also where marketing claims most sharply outrun what that evidence actually shows.

The key trial is Zhou et al. (Tulane University), published in Gut in 2019: a double-blind, placebo-controlled, 8-week RCT in adults with post-infectious diarrhea-predominant IBS (IBS-D) who had documented intestinal hyperpermeability at baseline. Participants took oral L-glutamine 5 g three times daily (15 g/day total) or placebo. The results were striking: the primary endpoint (a reduction of 50 or more points on the IBS Severity Scoring System) was met by 79.6% of the glutamine group vs. 5.8% of the placebo group — roughly a 14-fold difference. IBS-SS scores fell from 301 to 181 (p<0.0001), and the elevated urinary lactulose/mannitol ratio — the objective marker of intestinal permeability — normalized in the glutamine group (0.11 to 0.05, p<0.0001) but not in the placebo group (PMID 30108163).

Why this trial is unusually trustworthy: Zhou et al. was funded entirely by U.S. NIH/NIDDK grants (R01 DK099052, R01 DK118959, R21 AT005291, U54 GM104940), and the authors declared "Competing interests: None." This is genuinely independent, publicly funded research with no supplement-industry or pharmaceutical funding — a real strength for a result this dramatic (PMID 30108163).

But the caveats matter as much as the headline number. This was a single-center trial in a highly selected population: participants had to have both post-infectious IBS-D and measured hyperpermeability at baseline — a specific phenotype, not "IBS" or "leaky gut" in general. An accompanying editorial in Gut urged caution and called for larger replication before generalizing the findings, and the study authors themselves said the same (Ford & Gibson editorial, Gut 2019).

Most consumer "glutamine heals leaky gut" marketing aimed at healthy people or people with non-specific digestive complaints relies on animal studies and in-vitro cell-culture data, which are excluded from this review. In a general or healthy population, or for non-specific "leaky gut" complaints without documented post-infectious IBS-D and measured hyperpermeability, human trial evidence for glutamine-driven gut-barrier repair is Insufficient.

Irritable bowel syndrome (IBS)

Beyond the Zhou trial's narrow subgroup, there is no adequate independent RCT evidence that glutamine benefits IBS broadly — including IBS-C (constipation-predominant), mixed-type IBS, or IBS that did not follow a documented gastrointestinal infection. The overall grade for IBS as a general condition is Weak; it rises to Moderate only for the specific post-infectious IBS-D-with-hyperpermeability phenotype tested by Zhou et al. (Zhou et al., Gut 2019; Ford & Gibson editorial).

Inflammatory bowel disease — Crohn’s disease

A 2016 Cochrane systematic review (Akobeng, Elawad, and Gordon) examined glutamine for induction of remission in Crohn’s disease and found only 2 small RCTs totaling 42 patients. Neither trial showed benefit: a glutamine-enriched polymeric diet did not improve remission compared with a standard diet in children, and glutamine-supplemented total parenteral nutrition did not improve outcomes in adults. The GRADE quality of the underlying evidence was rated low to very low, and Cochrane concluded there is no evidence that glutamine is effective for active Crohn’s disease (PMID 26853855; full text, PMC10405219).

The review authors were affiliated with Sidra Medical & Research Center, the University of Manchester, and the University of Central Lancashire — academic institutions with no commercial funding disclosed, making this an independent, conflict-free null finding. Grade: Insufficient/Contested for Crohn’s disease.

Ulcerative colitis and IBD broadly

A 2021 systematic review of clinical trials by Severo et al. (Clin Nutr ESPEN) reviewed 7 RCTs of glutamine — oral doses of 21–30 g or 0.5 g/kg, enteral feeding, or parenteral dosing of 0.3 g/kg — across inflammatory bowel disease populations. The review concluded that glutamine had no effect on disease course, intestinal permeability, gut morphology, disease activity, symptoms, biochemical parameters, oxidative stress markers, or inflammation markers (PMID 33745622).

The review was conducted by academic authors at the Federal University of Piauí and the Federal University of Ceará in Brazil, with no commercial funding disclosed — independent. Grade: Insufficient for ulcerative colitis and IBD broadly. Combined with the Crohn’s-specific Cochrane review above, the human evidence across the IBD spectrum is consistently null.

Critical illness, trauma, burns, and surgery

This is the domain where glutamine was studied most heavily and marketed most confidently — and where the story has changed the most. It is also not, strictly speaking, a "gut health" claim, but it is essential context because it is where the largest, best-funded body of human glutamine trials exists, and because the safety signal from this literature is directly relevant to anyone considering high-dose glutamine.

REDOXS (Heyland et al., New England Journal of Medicine, 2013) was a landmark, 1,223-patient multicenter RCT across Canada, the U.S., and Europe in critically ill adults with multi-organ failure on mechanical ventilation. Patients received high-dose glutamine (given both intravenously and enterally) or placebo, started within 24 hours of ICU admission. The result reversed decades of assumption: 28-day mortality was 32.4% in the glutamine group vs. 27.2% in the placebo group (adjusted odds ratio 1.28, 95% CI 1.00–1.64, p=0.05), and in-hospital and 6-month mortality were also significantly higher with glutamine. There was no benefit on organ failure or infection rates (Heyland et al., NEJM 2013, PMID 23594003).

Why this result carries extra weight: REDOXS was funded by the Canadian Institutes of Health Research (CIHR), a public agency with no commercial stake in the outcome — which strengthens the credibility of a harm finding, since there was no financial incentive to find or report increased mortality. An independent editorial concluded the trial created genuine "uncertainty about the safety of supplemental glutamine" at high doses in the sickest patients (Mulherin & Sacks, Hepatobiliary Surg Nutr 2015).

SIGNET (Andrews et al., BMJ, 2011) was a 502-patient double-blind factorial RCT across 10 Scottish ICUs, testing parenteral glutamine (20.2 g/day) with or without selenium for up to 7 days in patients with gastrointestinal failure on parenteral nutrition. It found no overall effect of glutamine on new infections (odds ratio 1.07, 95% CI 0.75–1.53) and no mortality benefit (Andrews et al., BMJ 2011; PMID 21415104). SIGNET was funded by Scotland’s Chief Scientist Office — again independent public funding.

Pooling the field together, a meta-analysis of 47 RCTs (6,198 patients) found no significant reduction in hospital mortality with glutamine in critically ill patients overall, although it did shorten mechanical-ventilation duration; a subgroup analysis suggested a possible benefit only in severely burned patients (Sun et al., Ann Palliat Med 2021, PMID 33222464). Earlier, more optimistic meta-analyses in this field were dominated by smaller, sometimes industry-linked parenteral-glutamine trials; that positive signal largely disappeared once the large, independent REDOXS and SIGNET trials were included (Chen et al., Crit Care 2014).

Net assessment: Contemporary critical-care guidelines no longer recommend routine high-dose glutamine in critically ill patients, particularly those with renal or multi-organ failure. Grade: Contested — historically presented as glutamine’s strongest indication, but the largest independent RCT found harm, and pooled data show no routine benefit except a weak signal in severe burns (Weak).

Exercise, immune function, and muscle

The idea that falling plasma glutamine during overtraining causes immune suppression in athletes originates from an old observational study of plasma amino acids in overtrained athletes, not a controlled intervention trial (Parry-Billings et al., Med Sci Sports Exerc 1992). Independent reviews conclude that glutamine supplementation does not reliably prevent post-exercise immune suppression, upper-respiratory infections, or enhance muscle mass or performance in healthy athletes who already get adequate dietary protein (Cruzat et al., Nutrients 2018). A small 2024 RCT reported improved salivary IgA (a mucosal immunity marker) in combat-sport athletes, but it was small, single-site, and published in a sports-nutrition journal with industry-adjacent characteristics, so it should be treated as hypothesis-generating rather than confirmatory (Lu et al., J Int Soc Sports Nutr 2024). Grade: Weak — biochemical and surrogate endpoints only, with no consistent clinical benefit.

Sickle cell disease and "FDA-recognized" marketing

For completeness and to correct a common marketing distortion: the only FDA-approved therapeutic use of pharmaceutical-grade L-glutamine is Endari (Emmaus Medical), approved to reduce acute painful crises in sickle cell disease, based on RCT evidence specific to that condition (LiverTox, NIH NBK573011). This is a genuinely Strong evidence base — but it has nothing to do with gut health. Supplement marketing sometimes invokes "FDA-recognized" or "FDA-approved" glutamine without clarifying that the approval covers sickle cell pain crises specifically, not leaky gut, IBS, or general digestive wellness. Readers should treat any such phrasing as a red flag for imprecise or misleading marketing.

What works and what does not

Claim Verdict Notes
Normalizing intestinal permeability in post-infectious IBS-D with documented hyperpermeability Works, in this narrow group Single strong independent RCT, 79.6% vs. 5.8% responders (Zhou et al. 2019); needs independent multicenter replication
"Healing leaky gut" in healthy people or non-specific complaints Not supported Relies on excluded animal/in-vitro data; no adequate human RCT in general populations
General IBS (all subtypes) Not supported beyond the post-infectious IBS-D subgroup No adequate independent RCT (Zhou et al. 2019)
Crohn’s disease remission Does not work Cochrane: 2 RCTs, 42 patients, no benefit, low/very-low GRADE (PMID 26853855)
Ulcerative colitis / IBD broadly Does not work Systematic review of 7 RCTs: no effect on any outcome measured (PMID 33745622)
Routine high-dose glutamine in critical illness Does not work, and may cause harm REDOXS found increased mortality; SIGNET and the 47-RCT meta-analysis found no benefit (PMID 23594003; PMID 21415104; PMID 33222464)
Severe burns (subgroup) Possible modest benefit Weak meta-analysis subgroup signal only; not a dedicated confirmatory RCT (PMID 33222464)
Exercise recovery, immune support, muscle preservation in healthy athletes Not convincingly supported Surrogate markers only; no consistent clinical benefit (Cruzat et al. 2018)
Sickle cell pain crisis reduction (Endari) Works, but is not a gut-health claim FDA-approved drug based on RCT evidence (NBK573011)

Risks and all side effects

Effect / concern Frequency / certainty Evidence Notes
General tolerability at 15–30 g/day, short term Well tolerated; adverse events low and similar to placebo in the Zhou IBS RCT Zhou et al., Gut 2019 No serious adverse events reported at this oral dose over 8 weeks
Increased mortality in critical illness (high-dose IV + enteral) Statistically significant in a large independent RCT Heyland et al. (REDOXS), NEJM 2013; Mulherin & Sacks editorial Specific to critically ill patients with multi-organ failure receiving high-dose combined IV and enteral glutamine — not the same population or dose as typical oral supplement use
Liver injury Not associated with idiosyncratic liver injury in standard supplement use per LiverTox; one case report exists LiverTox NBK573011; Hatami et al. 2020 A case report links hepatotoxicity to high-dose sports glutamine powder; treat megadose or unverified products with caution
Hepatic encephalopathy / cirrhosis risk Theoretical concern in advanced liver disease Rama Rao & Norenberg, Neurochem Res 2013 Glutamine metabolizes to glutamate plus ammonia; in cirrhosis, impaired ammonia clearance raises theoretical risk of astrocyte swelling (the "Trojan horse" hypothesis). This mechanism is derived substantially from non-human/animal data and is flagged as such — but the underlying concern (impaired ammonia clearance in liver disease) is a well-established human clinical fact independent of glutamine
Renal dysfunction Guideline-level caution Vanek et al. review Added nitrogen load is a concern in people with significant kidney impairment
MSG/glutamate sensitivity Low-certainty, theoretical General clinical caution; no strong causal human trial evidence Glutamine is a glutamate precursor; people who report MSG sensitivity may wish to avoid it as a precaution even though causal evidence is weak

All interactions

Substance / condition Interaction / mechanism Severity / status Source
Cirrhosis / hepatic encephalopathy medications and management Glutamine is metabolized to glutamate and ammonia; impaired hepatic ammonia clearance in advanced liver disease raises a theoretical risk of worsening encephalopathy Use with caution; avoid without hepatology guidance Rama Rao & Norenberg 2013; LiverTox NBK573011
Lactulose Both glutamine metabolism and lactulose therapy affect ammonia handling; theoretical interaction, low-certainty Caution, low-certainty LiverTox NBK573011
Anti-seizure medications Theoretical interaction via glutamate pathway (glutamine is a glutamate precursor) Low-certainty theoretical caution LiverTox NBK573011
Chemotherapy / critical illness nutrition regimens with high-dose IV glutamine REDOXS showed increased mortality when high-dose glutamine was added to nutrition support in multi-organ failure Avoid routine high-dose IV/enteral glutamine in critical illness outside specific protocols Heyland et al., NEJM 2013
Common medications generally (anticoagulants, antidepressants, antidiabetics, antihypertensives) No major well-documented drug interactions identified in independent databases No strong signal identified; data gap for some drug classes, not proof of safety LiverTox NBK573011
Data gap disclosure: Independent, systematic human drug-interaction studies specific to oral L-glutamine at typical supplement doses are limited. The interactions above reflect the best available independent sources; absence of a documented interaction is not proof of safety, particularly in people with liver or kidney disease or those in critical care settings.

Who should avoid L-glutamine

  • People with cirrhosis or a history of hepatic encephalopathy should avoid supplemental glutamine without hepatology guidance, given the theoretical ammonia-clearance concern (Rama Rao & Norenberg 2013).
  • People with significant renal impairment should use caution because of the added nitrogen load (Vanek et al. review).
  • Critically ill patients with multi-organ failure, especially those on mechanical ventilation, should not receive routine high-dose glutamine (IV or combined IV/enteral) given the mortality signal in REDOXS — this is now reflected in the fact that contemporary critical-care guidelines no longer recommend routine high-dose glutamine in this population (Heyland et al., NEJM 2013).
  • People with MSG or glutamate sensitivity may reasonably choose to avoid glutamine as a precaution, even though the human causal evidence for a reaction is weak.
  • Anyone expecting general "leaky gut" repair, IBS relief outside the post-infectious IBS-D-with-hyperpermeability phenotype, or benefit for Crohn’s disease or ulcerative colitis should not rely on glutamine, since human trials do not support these broader uses (PMID 26853855; PMID 33745622).

Dosage and how to take it

Use case Studied dose Duration Notes
Post-infectious IBS-D with documented hyperpermeability 15 g/day oral (5 g three times daily) 8 weeks in the supporting RCT Only demonstrated effective in this specific, medically documented phenotype; not a general IBS or "gut health" dosing recommendation (Zhou et al. 2019)
Crohn’s disease / IBD (as studied, not recommended) Oral, enteral, or parenteral regimens, 21–30 g oral or 0.3–0.5 g/kg in various trials Varied by trial No benefit demonstrated; not a recommended use (PMID 26853855; PMID 33745622)
Critical illness (as studied, not recommended routinely) High-dose IV + enteral combined regimens (REDOXS); ~20.2 g/day parenteral (SIGNET) Up to 7 days or longer in ICU protocols Associated with increased mortality in multi-organ failure; not recommended routinely by contemporary guidelines (PMID 23594003)
General oral supplement use Commonly 5–20 g/day in consumer products Variable Well tolerated short-term at 15–30 g/day in healthy adults per available trial safety data, but general "gut health" benefit at this dose lacks supporting evidence outside the specific IBS-D subgroup

Funding tracing and regulatory status

How industry funding shaped the glutamine literature

The positive early parenteral-glutamine literature — much of which drove decades of critical-care enthusiasm for the ingredient — was substantially shaped by manufacturers of glutamine-dipeptide parenteral nutrition products, notably Fresenius Kabi (maker of Dipeptiven/Ala-Gln) and amino-acid producers such as Ajinomoto, whose products underpinned many smaller European parenteral-nutrition trials. This is a widely recognized reason the field skewed positive before the largest independent trials were run (Vanek et al. review; Fürst et al.).

By contrast, the trials that ultimately reversed the field’s conclusions were all publicly funded and independent: REDOXS was funded by Canada’s CIHR, SIGNET by Scotland’s Chief Scientist Office, and the Zhou IBS-D trial by the U.S. NIH/NIDDK. The fact that the null and harm findings came from publicly funded, conflict-free research — while the earlier positive signal was industry-adjacent — increases confidence that the null/harm findings reflect the true state of the evidence rather than funding-driven bias (PMID 23594003; PMID 21415104; PMID 30108163).

Source Funding Independence rating Notes
Zhou et al., Gut 2019 (IBS-D permeability RCT) NIH/NIDDK grants Independent Authors declared no competing interests (PMID 30108163)
Akobeng et al., Cochrane 2016 (Crohn’s review) Cochrane; academic institutions Independent No commercial funding disclosed (PMID 26853855)
Severo et al., Clin Nutr ESPEN 2021 (IBD review) Brazilian public universities Independent No commercial funding disclosed (PMID 33745622)
Heyland et al., NEJM 2013 (REDOXS) Canadian Institutes of Health Research (CIHR) Independent, public No industry funding; harm finding carries added credibility given no financial upside to reporting harm (PMID 23594003)
Andrews et al., BMJ 2011 (SIGNET) Chief Scientist Office, Scotland Independent, public Academic, no industry funding (PMID 21415104)
Early positive parenteral-glutamine trials (pre-REDOXS/SIGNET era) Substantially shaped by Fresenius Kabi and Ajinomoto-linked product use Industry-adjacent Smaller European trials; positive effect largely disappeared once large independent trials were included (Chen et al., Crit Care 2014)

Regulatory status

  • US FDA: L-glutamine (CAS 56-85-9) is listed as an added-to-food substance and is Generally Recognized as Safe (GRAS) for use as a nutrient supplement and flavor enhancer under 21 CFR 172.320 (FDA Substances Added to Food: L-Glutamine). Sold as a dietary supplement, it is not regulated or reviewed as a drug for general gut-health use.
  • Endari is the sole FDA-approved drug form of L-glutamine, approved specifically for reducing acute painful crises in sickle cell disease — a distinct regulatory pathway with distinct RCT evidence, unrelated to gut health (LiverTox NBK573011).
  • EU/EFSA: L-glutamine is an authorized amino acid for foods, food supplements, and parenteral nutrition; EFSA has assessed amino acid sources for safety in these contexts (EFSA news).

Frequently asked questions

Does L-glutamine heal "leaky gut"?

Only in a narrow, medically documented subgroup: adults with post-infectious diarrhea-predominant IBS who have measured intestinal hyperpermeability. In that specific group, a well-designed, NIH-funded RCT found 15 g/day normalized permeability markers and produced a large symptom improvement (Zhou et al., Gut 2019). For healthy people or non-specific "leaky gut" complaints without that diagnosis, the claim is not supported by human trials and relies on excluded animal/in-vitro research.

Does glutamine help Crohn’s disease or ulcerative colitis?

No. A Cochrane review found no benefit in Crohn’s disease across the available trials (PMID 26853855), and a separate systematic review found no effect on disease course, permeability, or inflammation markers across ulcerative colitis and IBD trials generally (PMID 33745622).

Is L-glutamine dangerous?

At typical oral supplement doses (15–30 g/day) in short-term trials, it has been well tolerated. The important exception is critical illness: in critically ill patients with multi-organ failure, a large independent trial found that high-dose glutamine (given IV and enterally) increased mortality (REDOXS, NEJM 2013). People with cirrhosis, hepatic encephalopathy, or significant kidney disease should also use caution.

Is L-glutamine FDA-approved?

As a dietary ingredient, L-glutamine is GRAS (Generally Recognized as Safe) under FDA food regulations, not an approved drug. The one FDA-approved drug form, Endari, is approved only for reducing pain crises in sickle cell disease — not for gut health, leaky gut, or IBS (LiverTox NBK573011).

Should critically ill patients take glutamine?

Not routinely at high doses. The largest independent trial (REDOXS) found increased mortality in critically ill patients with multi-organ failure who received high-dose glutamine, and a 47-RCT meta-analysis found no overall mortality benefit, with only a weak signal in severe burns (PMID 23594003; PMID 33222464). Contemporary critical-care guidelines reflect this shift away from routine high-dose use.

Does glutamine help athletes or exercise recovery?

Evidence is weak. Independent reviews find no consistent clinical benefit for immune support, recovery, or muscle preservation in healthy athletes with adequate protein intake — benefits are limited to surrogate biochemical markers rather than reliable clinical outcomes (Cruzat et al., Nutrients 2018).

Sources and funding notes

Last reviewed: July 4, 2026.

Leave a Comment